Ixabepilone Contents History Pharmacology Approval Clinical uses References External links Navigation menuMonographa608042IxabepiloneWHO219989-84-164455406824DB0484520145579K27005NP0AD04645ChEMBL1201752100.158.736Interactive image(verify)"Novel cytotoxic agents: epothilones"10.2146/ajhp0800891846332710.1007/s00280-008-0724-81834779510.1007/s00280-015-2863-z26416565"Ixabepilone for the treatment of solid tumors: a review of clinical data"10.1517/13543784.17.3.42318321240"Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer"10.2146/ajhp0706281894586010.1586/14737140.8.6.99318533808Medical News Today"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment"10.1200/JCO.2007.12.655717968020"Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas"10.1200/JCO.2006.08.730417261851Ixempra product websiteIxempra prescribing informatione

Vinca alkaloidsVinblastineVincristineVinflunineVindesineVinorelbineTaxanesCabazitaxelDocetaxelLarotaxelOrtataxelPaclitaxelTesetaxelEpothilonesIxabepiloneDihydrofolate reductase inhibitorAminopterinMethotrexatePemetrexedPralatrexateThymidylate synthase inhibitorRaltitrexedPemetrexedAdenosine deaminase inhibitorPentostatinHalogenatedribonucleotide reductase inhibitorsCladribineClofarabineFludarabineNelarabineThiopurineTioguanineMercaptopurineThymidylate synthase inhibitorFluorouracilCapecitabineDoxifluridineTegafur+gimeracil/oteracilCarmofurFloxuridineDNA polymerase inhibitorCytarabineRibonucleotide reductase inhibitorGemcitabineHypomethylating agentAzacitidineDecitabineRibonucleotide reductase inhibitorHydroxycarbamideCamptothecaCamptothecinCositecanBelotecanGimatecanExatecanIrinotecanLurtotecanSilatecanTopotecanRubitecanPodophyllumEtoposideTeniposideAnthracyclinesAclarubicinDaunorubicinDoxorubicinEpirubicinIdarubicinAmrubicinPirarubicinValrubicinZorubicinAnthracenedionesMitoxantronePixantroneNitrogen mustardsChlormethineCyclophosphamideIfosfamideTrofosfamideChlorambucilMelphalanPrednimustineBendamustineUramustineNitrosoureasCarmustineLomustineSemustineFotemustineNimustineRanimustineStreptozocinAlkyl sulfonatesBusulfanMannosulfanTreosulfanAziridinesCarboquoneThiotepaTriaziquoneTriethylenemelamineCarboplatinCisplatinDicycloplatinNedaplatinOxaliplatinSatraplatinHydrazinesProcarbazineTriazenesDacarbazineTemozolomideAltretamineMitobronitolPipobromanStreptomycesActinomycinBleomycinMitomycinsPlicamycinFITipifarnibCDKinhibitorsAbemaciclibAlvocidibPalbociclibRibociclibSeliciclibPrIBortezomibCarfilzomibIxazomibPhIAnagrelideIMPDITiazofurinLIMasoprocolPARP inhibitorNiraparibOlaparibRucaparibHDACBelinostatPanobinostatRomidepsinVorinostatPIKIIdelalisibERAAtrasentanRetinoid X receptorBexaroteneSex steroidTestolactoneAmsacrineTrabectedinRetinoidsAlitretinoinTretinoinArsenic trioxideAsparagine depletersAsparaginasePegaspargaseCelecoxibDemecolcineElesclomolElsamitrucinEstramustine phosphateEtoglucidLonidamineLucanthoneMitoguazoneMitotaneOblimersenOmacetaxine mepesuccinateEribulin


Bristol-Myers SquibbMitotic inhibitorsThiazolesEpoxidesLactams


INNBristol-Myers Squibbchemotherapeuticsemi-syntheticanalogepothilonemetabolic stabilitypharmacokineticsmedicinal chemistryTaxolmicrotubulesFood and Drug Administrationmetastaticbreast cancerEMEAcapecitabineanthracyclinetaxanenon-Hodgkin's lymphoma
























































Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.[1]




Contents





  • 1 History


  • 2 Pharmacology


  • 3 Approval


  • 4 Clinical uses


  • 5 References


  • 6 External links




History


Ixabepilone is a semi-synthetic analog of epothilone B, a natural chemical compound produced by Sorangium cellulosum.[2] Epothilone B itself could not be developed as a pharmaceutical drug because of poor metabolic stability and pharmacokinetics.[3] Ixabepilone was designed through medicinal chemistry to improve upon these properties.[3]



Pharmacology


Much like Taxol, Ixabepilone acts to stabilize microtubules.[4][5][6]
It is highly potent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to taxane type drugs.[7]



Approval


On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies.[8] In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone.[9]


Ixabepilone is administered through injection, and is marketed under the trade name Ixempra.



Clinical uses


Ixabepilone, in combination with capecitabine, has demonstrated effectiveness in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.[10]


It has been investigated for use in treatment of non-Hodgkin's lymphoma.[11]
In pancreatic cancer phase two trial it showed some promising results (used alone). Combination therapy trials are ongoing.[7]



References




  1. ^ http://www.cancer.org/Treatment/TreatmentsandSideEffects/GuidetoCancerDrugs/Ixabepilone


  2. ^ Goodin S (May 2008). "Novel cytotoxic agents: epothilones". Am J Health Syst Pharm. 65 (10 Suppl 3): S10–5. doi:10.2146/ajhp080089. PMID 18463327..mw-parser-output cite.citationfont-style:inherit.mw-parser-output .citation qquotes:"""""""'""'".mw-parser-output .citation .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .citation .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-ws-icon abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center.mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-maintdisplay:none;color:#33aa33;margin-left:0.3em.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em


  3. ^ ab Lee FY, Borzilleri R, Fairchild CR, et al. (December 2008). "Preclinical discovery of ixabepilone, a highly active antineoplastic agent". Cancer Chemother. Pharmacol. 63 (1): 157–66. doi:10.1007/s00280-008-0724-8. PMID 18347795.


  4. ^ Lopus, M; Smiyun, G; Miller, H; Oroudjev, E; Wilson, L; Jordan, MA (2015). "Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype". Cancer Chemother Pharmacol. 76: 1013–24. doi:10.1007/s00280-015-2863-z. PMID 26416565.


  5. ^ Denduluri N, Swain SM (March 2008). "Ixabepilone for the treatment of solid tumors: a review of clinical data". Expert Opin Investig Drugs. 17 (3): 423–35. doi:10.1517/13543784.17.3.423. PMID 18321240.


  6. ^ Goodin S (November 2008). "Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer". Am J Health Syst Pharm. 65 (21): 2017–26. doi:10.2146/ajhp070628. PMID 18945860.


  7. ^ ab M. Vulfovich; Rocha-Lima, C; et al. (2008). "Novel advances in pancreatic cancer treatment". Expert Rev Anticancer Ther. 8 (6): 993–1002. doi:10.1586/14737140.8.6.993. PMID 18533808.


  8. ^ Medical News Today


  9. ^ London, 20 November 2008 Doc. Ref. EMEA/602569/2008


  10. ^ Thomas ES, Gomez HL, Li RK, et al. (November 2007). "Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment". J. Clin. Oncol. 25 (33): 5210–7. doi:10.1200/JCO.2007.12.6557. PMID 17968020.


  11. ^ Aghajanian C, Burris HA, Jones S, et al. (March 2007). "Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas". J. Clin. Oncol. 25 (9): 1082–8. doi:10.1200/JCO.2006.08.7304. PMID 17261851.



External links


  • Ixempra product website

  • Ixempra prescribing information

Ixabepilone
Ixabepilone.svg
Clinical data
Trade namesIxempra
SynonymsAzaepothilone B

AHFS/Drugs.com
Monograph
MedlinePlusa608042
License data


  • US FDA: Ixabepilone

Pregnancy
category


  • US: D (Evidence of risk)

Routes of
administration		Intravenous infusion
ATC code

  • L01DC04 (WHO)
Legal status
Legal status


  • US: ℞-only


Pharmacokinetic data
BioavailabilityN/A
Protein binding67 to 77%
MetabolismExtensive, hepatic, CYP3A4-mediated
Elimination half-life
52 hours
ExcretionFecal (mostly) and renal
Identifiers
CAS Number

  • 219989-84-1 ☒N

PubChem CID
  • 6445540
IUPHAR/BPS
  • 6824
DrugBank

  • DB04845 ☑Y
ChemSpider

  • 20145579 ☑Y
UNII
  • K27005NP0A
KEGG

  • D04645 ☑Y
ChEMBL

  • ChEMBL1201752 ☒N
ECHA InfoCard
100.158.736 Edit this at Wikidata
Chemical and physical data
Formula
C27H42N2O5S
Molar mass506.698 g/mol g·mol−1
3D model (JSmol)
  • Interactive image

.mw-parser-output .noboldfont-weight:normal
 ☒N☑Y (what is this?)
  (verify)














-

Popular posts from this blog

Moe incest case Sentencing See also References Navigation menu"'Australian Josef Fritzl' fathered four children by daughter""Small town recoils in horror at 'Australian Fritzl' incest case""Victorian rape allegations echo Fritzl case - Just In (Australian Broadcasting Corporation)""Incest father jailed for 22 years""'Australian Fritzl' sentenced to 22 years in prison for abusing daughter for three decades""RSJ v The Queen"

2009 crimes in AustraliaPeople convicted of incestRape in AustraliaChild abuse incidents and cases Victoria Police Moe, Victoria, Australiarapedphysically abusedviolencediedallegationsNews LimitedinvestigateMelbournedevelopmental problemsintellectually disabledspeech impedimentbirth certificateschargedsexual abuseDNA testspleadedguiltyincestindecent assaultcommon assaultsentencingimprisonmentparolesex offender registryappeal The Moe incest case emerged in February 2007 when a woman, identified as M for legal reasons, reported to Victoria Police in the town of Moe, Victoria, Australia that her 63-year-old father, RSJ, had raped, [1] [2] physically abused, and kept her a virtual prisoner in her own home between 1977 and 2005. Police had known about the alleged abuse since 2005, when M first came forward, but could not act because she did not want to cooperate after her father threatened violence against her mother and siblings. The J family had been known to authorities for more than ...
Read more

John Burke, 9th Earl of Clanricarde References Navigation menuA General and heraldic dictionary of the peerage and baronetage of the British EmpireLeigh Rayment's Peerage Pages

People from County GalwayJacobite military personnel of the Williamite War in IrelandHouse of Burke1642 births1722 deathsMembers of the Irish House of LordsEarls of ClanricardePeers of Ireland created by James II IrishpeerWilliam Burke, 7th Earl of ClanricardeRichardisle of InishbofinWilliamite War in IrelandBattle of AughrimUlick Burke, 1st Viscount GalwayProtestantsprivate act of the English ParliamentCatholicWild GeeseSpainBolognaFontenoyHonora BurkePatrick Sarsfield, 1st Earl of Lucan John Burke, 9th Earl of Clanricarde (1642–1722) was an Irish peer. Burke was a younger son of William Burke, 7th Earl of Clanricarde and succeeded his brother Richard. He was created Baron Bophin (over the isle of Inishbofin where Burke is still a common surname amongst the islanders [1] ) in 1689 and commanded a foot regiment as its colonel during the Williamite War in Ireland. He was taken prisoner at the Battle of Aughrim in 1691 and outlawed. His younger brother Ulick Burke, 1st Viscount G...
Read more

Football at the 1986 Brunei Merdeka Games Contents Teams Group stage Knockout stage References Navigation menu"Brunei Merdeka Games 1986".

Image
1986 in Asian footballFootball at the Brunei Merdeka Games1986 in Brunei1986 in Singaporean football1986 in Malaysian football1986 in Thai sport Bandar Seri BegawanBruneiMalaysia Cup Football at the 1986 Brunei Merdeka Games Tournament details Host country Brunei Dates 19 July – 27 July Teams 10 Final positions Champions Persib Bandung (1st title) Runners-up Malaysia B Third place   Brunei Fourth place Singapore XI Tournament statistics Matches played 10 Goals scored 25 (2.5 per match) ← 1985 1987 → The football tournament at the 1986 Brunei Merdeka Games was held from July 19 to 27 in Bandar Seri Begawan, Brunei. The tournament was also referred to as the Sultan Hassanal Bolkiah Cup, or the second Brunei Pesta Sukan Cup. Contents 1 Teams 2 Group stage 2.1 Group A 2.2 Group B 3 Knockout stage 3.1 Semi-finals 3.2 Bronze medal match 3.3 Gold medal match 4 References Teams It is likely that the Philippines team was the full national team, bu...
Read more